Clinical Trial Update: Study of APG-2575 as a Single Agent or in Combination With Other Therapeutic Agents for CLL/SLL [Phase 1]

View source ↗

Summary

This clinical trial update describes a Phase 1 study of APG-2575, studied as a single agent or in combination with other therapies for chronic lymphocytic leuke…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Chronic Lymphocytic Leukemia
• Small Lymphocytic Lymphoma

Drugs mentioned

• APG-2575

Snippet

Sponsor: Ascentage Pharma Group Inc. | Conditions: CLL/SLL | Phase 1 | Status: RECRUITING